JT 001
Alternative Names: JT-001Latest Information Update: 10 Nov 2021
Price :
$50 *
At a glance
- Originator Jeil Pharmaceutical
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Type 2 diabetes mellitus
Most Recent Events
- 08 Nov 2021 Phase-III clinical trials in Type 2 diabetes mellitus (Adjunctive therapy) in South Korea (unspecified route) (NCT05101135)